Overview

A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Compared With Placebo in Adult Participants

Status:
Recruiting

Trial end date:
2024-04-03

Target enrollment:

Participant gender:

Summary

This first-in-human (FIH) study of VXX-401, an anti-PCSK9 peptide-based immunotherapeutic candidate, is designed to assess the safety, tolerability, immunogenicity, and pharmacodynamics (PD) of VXX-401 and to determine an optimal dose regimen for LDL-C lowering in subsequent clinical trials.

Phase:

Phase 1

Details

Lead Sponsor:

Vaxxinity, Inc.

Collaborator:

Novotech (Australia) Pty Limited